Mitochondrial potassium channel

Mitochondrial potassium channels are a diverse group of ion channels located on the inner membrane of mitochondria across various tissues. They include several molecular entities such as ATP-sensitive channels (mitoK_ATP), large-, intermediate-, and small-conductance Ca^2+-activated channels (e.g., mitoBK_Ca), voltage-gated types like Kv1.3/Kv7.4, two-pore domain TASK‐3 channels, and SLO2 sodium‐activated K^+ channels[1][6]. These channels regulate key aspects of cellular metabolism by controlling the flow of K^+ ions into mitochondria—modulating membrane potential (\( \Delta\psi_m \)), matrix volume homeostasis, respiratory chain activity, calcium handling capacity during stress responses like ischemia/reperfusion injury or oxidative damage—and influencing cell survival versus death decisions through effects on ROS generation. Pharmacologically targeting these channels has shown promise for cytoprotection in cardiac/neuronal tissue after injury as well as selective induction of apoptosis in cancer cells expressing specific subtypes such as Kv1.3[2][3][7]. However, challenges remain due to poor selectivity among available modulators/drugs which can lead to off-target toxicity within mitochondria-rich tissues. Overall these ion channels represent an emerging class of therapeutic targets with roles spanning cardiovascular protection against ischemic damage through metabolic modulation up to novel anti-cancer strategies exploiting their unique presence/functionality within tumor cell mitochondria[5].

Other names

mitoK channelmitochondrial K+ channelmitochondrial ATP-sensitive potassium channel (mitoK_ATP)mitochondrial large-conductance Ca2+-activated potassium channel (mitoBK_Ca)mitochondrial small-conductance Ca2+-activated potassium channel (mitoSK_Ca)mitochondrial voltage-gated potassium channels (e.g., mitoKv1.3, mitoKv7.4)mitochondrial two-pore domain TASK-3 potassium channelSLO2 channel[1][2][6]

– Channel openers increase K+ influx into mitochondria leading to mild depolarization of the inner membrane potential; this can reduce calcium overload and ROS production during ischemic events—providing cytoprotection. – Inhibitors such as those targeting Kv1.3 induce apoptosis in cancer cells by increasing ROS production and triggering the intrinsic apoptotic pathway.[7]